IP Library Granted Patent US 8,084,586
Granted Patent B2
US 8,084,586 · App. 12/433,149 · Granted Dec 27, 2011

Doxorubicin immunoassay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,586
App. No.
12/433,149
Granted
Dec 27, 2011
Kind
B2
Abstract

Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.

Claims (14)

1. A kit for determining the presence of doxorubicin in a patient sample comprising reagents in separate containers, one of the reagents being a conjugate of a carrier containing a functional amino or thiol group with a compound selected from the groups consisting of compounds of the formula:

wherein A is

Y is an organic spacing group;

X is a functional group capable of binding to the amino or thiol group in said carrier;

p is an integer from 0 to 1;

a 14-substituted doxorubicin of the formula:

wherein X, Y and p are as above and B is —CH 2 — or;

and mixtures of a conjugate of a carrier with the compound of formula II-A and a conjugate of a carrier with the compound of formula II-B; and the other reagent being an antibody substantially selectively reactive with doxorubicin and not substantially cross-reactive to doxorubicin aglycone.

2. The kit of claim 1 , wherein said conjugate is present in a predetermined amount in said first container.

3. The kit of claim 2 , wherein said kit is used to determine the amount of doxorubicin in said sample.

4. The kit of claim 1 , wherein, said antibody is generated from a conjugate of immunogenic carrier having a terminal functional amino or thiol group linked to said 13-substituted or 14-substituted doxorubicin.

5. The kit of claim 4 , wherein said conjugate is said 13-substituted doxorubicin.

6. The kit of claim 5 , wherein said carrier has a reactive terminal functional thiol group and X is a terminal functional group capable of binding to said thiol group.

7. The kit of claim 6 , wherein X is

Assignments (1)
SECURITY INTEREST Recorded Nov 17, 2015
From: SALADAX BIOMEDICAL, INC.
To: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Reel/Frame 037126/0733 →